SIENNA: Lightweight Generalizable Machine Learning Platform for Brain Tumor Diagnostics

Sreya Sunil; Rahul S. Rajeev; Ayan Chatterjee; Julie Pilitsis; Amitava Mukherjee; Janet L. Paluh

doi:10.1101/2024.04.03.24305210

ABSTRACT

The transformative integration of Machine Learning (ML) for Artificial General Intelligence (AGI)-enhanced clinical imaging diagnostics, is itself in development. In brain tumor pathologies, magnetic resonance imaging (MRI) is a critical step that impacts the decision for invasive surgery, yet expert MRI tumor typing is inconsistent and misdiagnosis can reach levels as high as 85%. Current state-of-the-art (SOTA) ML brain tumor models struggle with data overfitting and susceptibility to shortcut learning, further exacerbated in large-sized models with many tunable parameters. In a comparison with multiple SOTA models, our deep ML brain tumor diagnostics model, SIENNA, surpassed limitations in four key areas of prioritized minimal data preprocessing, an optimized architecture that reduces shortcut learning and overfitting, integrated inductive cross-validation method for generalizability, and smaller neural architecture. SIENNA is applicable across MRI machines and 1.5 and 3.0 Tesla, and achieves high average accuracies on clinical DICOM MRI data across three-way classification: 92% (non-tumor), 91% (GBM), and 93% (MET) with retained high F1 and AUROC values for limited false positives/negatives. SIENNA is a lightweight clinical-ready AGI framework compatible with future multimodal expanded data integration.

Competing Interest Statement

SIENNA is patent pending in 63,465,719, an Artificial Intelligence System for Tumor Diagnostics of Clinical MRI Datasets. JLP, AM and AC are cofounders of the startup ITrakNeuro Inc. Dr. Pilitsis receives grant support from Medtronic, Boston Scientific, Abbott, NIH 2R01CA166379, NIH R01EB030324, and NIH U44NS115111. She is the medical advisor for Aim Medical Robotics and has stock equity.

Funding Statement

SIENNA analysis is supported by the State University of New York Research Foundation Technology Accelerator Fund (TAF) award.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of SUNY Polytechnic Institute, SUNY Albany gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes